Sciencedaily.com: A new drug shows preclinical efficacy in Rett syndrome

A new article published in the Cell Reports describes how a new drug is able to reduce the symptoms and activate the dormant neurons characteristic of Rett Syndrome in preclinical models. The study, led by Dr. Manel Esteller, Director of the Epigenetics and Cancer Biology Program (PEBC) of the Bellvitge

Read the full article at the original source

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.